Placebo News and Research

RSS

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

The US Food and Drugs Administration (FDA) has approved Byetta (exenatide) injection as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's add-on therapy is for those on glargine with metformin and/or a TZD (thiazolidinedione) or without.

20 Oct 2011

Rituximab may alleviate chronic fatigue syndrome through B-lymphocyte depletion

Chronic fatigue syndrome (CFS) may be alleviated by the anti-cancer drug Rituximab, suggesting that the source of the disease could lie in the immune system, according to a new study published Oct. 19 in the online journal PLoS ONE.

20 Oct 2011

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology's (ASN) Kidney Week 2011.

19 Oct 2011

Stochastic frontier estimation can identify problem of bias in self-reporting

Most people are rather vague when reporting on food and drink consumption, smoking and exercise habits. General practitioners, however, are skilled at interpreting phrases such as "I only have a few drinks rarely...each week" and "I get to the gym regularly" and can estimate based on symptoms and a person's physical appearance just how precise those claims are. However, it is crucial for healthcare research and epidemiology that relies on patient self-reporting that we find a more objective, rather than intuitive, way to identify bias in self-reporting.

18 Oct 2011

National Centre for Bowel Research and Surgical Innovation to be set up in London

A national research centre for bowel disease is to be set up in London to bring the Cinderella area of medicine to the forefront of surgical innovation.

18 Oct 2011

Accera identifies genetic profile of AD patients with heightened response to Axona

Accera, Inc., a biotech company specializing in cognitive health, announced today that it has identified the genetic profile of Alzheimer’s disease (AD) patients who have a high probability of responding to Axona (AC-1202), a prescription medical food product available at pharmacies nationwide.

18 Oct 2011

Natroba effective against head lice and nits

ParaPRO, LLC, announced that researchers have presented data showing the effectiveness of Natroba (spinosad) Topical Suspension, 0.9% against head lice and nits following one treatment without nit combing. Those data about the pediculicide, derived from a naturally-occurring soil bacterium, were presented in a poster session on Saturday, Oct. 15, 2011 at the American Academy of Pediatrics National Conference and Exhibition in Boston.

18 Oct 2011

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.

18 Oct 2011

Tailored postoperative treatment plan for women at high risk for severe pain after cesarean delivery

Nearly one third of children in the U.S. are born by cesarean delivery, a surgery that puts women at risk for persistent pain and postpartum depression. A new study presented at ANESTHESIOLOGY 2011 investigated whether an increase in pain treatment in patients at high risk for severe pain after surgery reduces these complications after a cesarean delivery.

18 Oct 2011

Functional MRI examines brain activation in individuals with low and high LRs to alcohol

A low level of response (LR) to alcohol reflects at least in part a low brain response to alcohol and carries significant risk for the later development of alcoholism. This study used functional magnetic resonance imaging (fMRI) to examine brain activation in individuals with low and high LRs to alcohol while they performed a cognitive task.

15 Oct 2011

New onset tenderness after combo hormone therapy increases risk of breast cancer

Post-menopausal women who experience new onset breast tenderness after starting combination hormone therapy may have an increased risk of breast cancer compared to women who don't experience breast tenderness, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has shown.

15 Oct 2011

Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV

Anadys Pharmaceuticals, Inc. today released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients.

14 Oct 2011

Cord blood stem cells can repair cardiac muscle after heart attack

At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient's own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and ageing. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart attack.

14 Oct 2011

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.

14 Oct 2011

High dose vitamin E supplements may raise risk of prostate cancer: Study

The chances of developing the disease rose by 17 per cent, even years after men stopped taking the vitamin, claim researchers. This comes right after the study which found women taking multivitamins and other supplements have an increased risk of dying.

13 Oct 2011

Vitamin E supplements linked with increased risk of prostate cancer

Men who took 400 international units (I.U.) of vitamin E daily had more prostate cancers compared to men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention (SELECT) Trial.

12 Oct 2011

Daily vitamin E supplementation may increase risk of prostate cancer

In a trial that included about 35,000 men, those who were randomized to receive daily supplementation with vitamin E had a significantly increased risk of prostate cancer, according to a study in the October 12 issue of JAMA.

12 Oct 2011

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.

12 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study

BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.

11 Oct 2011

Placebo News and Research

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Rituximab may alleviate chronic fatigue syndrome through B-lymphocyte depletion

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Stochastic frontier estimation can identify problem of bias in self-reporting

National Centre for Bowel Research and Surgical Innovation to be set up in London

Accera identifies genetic profile of AD patients with heightened response to Axona

Natroba effective against head lice and nits

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

Tailored postoperative treatment plan for women at high risk for severe pain after cesarean delivery

Functional MRI examines brain activation in individuals with low and high LRs to alcohol

New onset tenderness after combo hormone therapy increases risk of breast cancer

Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV

Cord blood stem cells can repair cardiac muscle after heart attack

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

High dose vitamin E supplements may raise risk of prostate cancer: Study

Vitamin E supplements linked with increased risk of prostate cancer

Daily vitamin E supplementation may increase risk of prostate cancer

Shield commences two ST10 Phase 3 studies in iron deficiency anaemia

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

DMC completes review of BioSante's LibiGel Phase III cardiovascular and breast cancer study

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News